Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20265 Citations
Enfuvirtide (Fuzeon)36 residuesYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Enfuvirtide (Fuzeon) is the only FDA-approved HIV fusion inhibitor, a 36-amino-acid peptide that blocks viral entry at the gp41 level. TORO trial data showed strong viral suppression, but 98% injection site reaction rates and twice-daily dosing led to its US discontinuation in February 2025.
90mcg · 2x Daily
Summary: Add 1.1mL BAC water to your 108mg vial. Draw to < 0.1 units on a U-100 syringe for a 90mcg dose. This vial will last 1200 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 90mg | 2x Daily |
| Moderate | 90mg | 2x Daily |
| Aggressive | 90mg | 2x Daily |
Each vial contains 108 mg of lyophilized powder. Add 1.1 mL of Sterile Water for Injection (SWFI only, not bacteriostatic water) to get roughly 90 mg/mL. Draw 1.0 mL to deliver the 90 mg dose. The reconstitution takes patience. Tap the vial gently for 10 seconds, roll between your palms, then wait. Full dissolution can take up to 45 minutes. Don't rush it. Injecting undissolved powder is a real problem, not a theoretical one. The solution should be completely clear, colorless, and free of bubbles before you draw. Refrigerate after reconstitution at 2 to 8 degrees C. Use within 24 hours. There's no preservative, so leftover solution gets discarded. One thing most people miss: never inject cold solution. Pull the vial from the fridge and let it warm to room temperature for 10 to 15 minutes before injection. Cold subcutaneous injections increase local pain considerably.
Dosing based on FUZEON (enfuvirtide) FDA Prescribing Information (2018) — 8 published references.View all sources →
Cross-check your Enfuvirtide (Fuzeon) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Enfuvirtide (Fuzeon) is the only FDA-approved HIV fusion inhibitor, a 36-amino-acid peptide that blocks viral entry at the gp41 level. TORO trial data showed strong viral suppression, but 98% injection site reaction rates and twice-daily dosing led to its US discontinuation in February 2025.
